The Non-Financial Ledger: What Numbers Cannot Capture

Imagine your child has a rare genetic disease. The kind that makes other doctors shrug and say there is nothing they can do. Then you learn there is a drug. One drug. It works. And it costs as much as a house every single year.

For the roughly 11,000 patients on Soliris worldwide, that reality was not hypothetical. Alexion’s drug treated conditions like paroxysmal nocturnal hemoglobinuria and atrial hemolytic uremic syndrome, diseases that destroy red blood cells and can be fatal without intervention. Soliris was, for many of these patients, the difference between living and dying. Alexion knew that. The company built its entire pricing strategy around it.

The SEC investigation and the subsequent shareholder lawsuit revealed a company that allegedly treated desperate patients less like human beings and more like identified revenue units. Court documents describe Alexion deploying “extreme fear tactics” to recruit patients and retain them. The company allegedly obtained data from partner laboratories to identify potential customers before those patients had even been formally diagnosed or referred. Think about what that means in practice: a pharmaceutical company mining lab data to find sick people before they knew they were sick, so a sales rep could get there first.

In Brazil, according to the shareholder class action, Alexion allegedly funded patient advocacy groups to file lawsuits against the Brazilian government. The purpose was to legally compel the government to reimburse patients for Soliris, instead of Alexion simply negotiating a lower price with Brazilian health authorities. Patients were used as legal instruments. Their suffering was leveraged to protect a price point. The advocacy groups that were supposed to represent patients were, according to the lawsuit, receiving Alexion grants to serve Alexion’s financial interests instead.

In Japan, Brazil, Russia, and Turkey, the SEC investigation found possible evidence of payments to foreign government officials and political parties. These were not abstract accounting irregularities. They were alleged payments designed to ensure that the governments of those countries would continue covering Soliris at a price that no functioning public health system would agree to under fair market conditions. The patients in those countries had no say. The governments that were supposed to bargain on their behalf were, allegedly, being paid not to.

When the SEC investigation became public, Soliris patients faced a different kind of harm: the possibility that the only drug keeping them alive was made by a company under federal investigation for corruption. The drug doesn’t become less effective. But the knowledge that your dependence on it has been commercially exploited in the way these documents describe carries its own weight.

The $125 million class action settlement sounds like accountability. For the shareholders who sued, it was a partial remedy for investment losses caused by Alexion’s alleged misrepresentations. For the patients, there was no settlement. There was no check. There is no line in the court documents where someone acknowledges that charging $700,000 a year for a drug while allegedly bribing foreign officials to keep that price intact is a harm to the people who depend on the drug. That ledger remains open and unpaid.

Legal Receipts: What They Said in Writing

These are direct quotes and findings from the court record. Nothing paraphrased, nothing invented.

“Alexion Pharmaceuticals, Inc. develops therapies for people living with rare disorders… Soliris had a retail price of $500,000 to $700,000 for each patient. To find and retain these uncommon but highly lucrative patients, Alexion allegedly engaged in extreme business practices.”

— Delaware Supreme Court opinion, citing the case record

• The court’s use of “highly lucrative patients” is the pharmaceutical industry’s business model stripped to its core. These are not customers. They are rare, identified, trapped revenue sources. The word “retain” applies to both clients and captives.
• The phrase “extreme business practices” is the court’s own characterization, drawn from the case record. It was extreme enough to trigger a formal SEC investigation.

“The SEC Investigation Order raised possible violations of the federal securities laws involving inaccurate annual 8-K, 10-K, and 10-Q reports; failure to maintain adequate books and records; failure to maintain an adequate system of internal accounting controls; and bribing foreign officials and political parties.”

— Delaware Supreme Court opinion, summarizing SEC Investigation Order

• These are not suspicions or rumors. The SEC issued a formal investigation order. That order identified four distinct categories of possible violation, including direct bribery of foreign government officials.
• Inaccurate 8-K, 10-K, and 10-Q reports are the filings that public investors rely on to decide whether to buy or sell a company’s stock. If those reports were inaccurate, investors were making decisions based on false information.

“The SEC Subpoena sought all documents relating to Alexion’s grant-making worldwide; statements regarding the recall of certain lots of Soliris; compliance with the Foreign Corrupt Practices Act, including gifts and payments to public health institutions and government agents; and lobbying efforts worldwide, especially in Japan, Brazil, Russia, and Turkey.”

— Delaware Supreme Court opinion, summarizing SEC Subpoena

• The subpoena covered Alexion’s activities across at least five countries. The FCPA exists specifically to prohibit American companies from bribing foreign government officials to win or maintain business.
• The reference to “public health institutions and government agents” is key. These are the exact people who decide whether a government pays for an expensive drug. Payments flowing to these decision-makers while Soliris pricing negotiations were active is the textbook definition of what the FCPA was written to stop.

The above language is from Alexion’s own 2015 Notice to its Tower 1 insurers, sent June 18, 2015. Alexion wrote it. Alexion signed it. Alexion sent it.

— 2015 Notice, A530-531, as quoted in Delaware Supreme Court opinion

• This is Alexion telling its own insurers, in 2015, that private lawsuits were likely to follow from the SEC investigation. When the shareholder class action was filed in December 2016, it was exactly the scenario Alexion had already predicted and disclosed to its insurers in writing.
• When Alexion later argued in court that the shareholder lawsuit was unrelated to the SEC investigation, it was directly contradicting the warning it had already submitted to its own Tower 1 insurers. The Delaware Supreme Court noticed. That is, in part, why Alexion lost.

“They alleged that Alexion improperly issued grants to patient advocacy groups in Brazil to sue the government for reimbursements for Soliris, rather than directly negotiate the price of Soliris with the Brazilian government.”

— Delaware Supreme Court opinion, summarizing Securities Class Action complaint

• This is the specific tactic at the center of the Brazil allegations. Instead of negotiating a lower price with the Brazilian government directly, Alexion allegedly funded the lawsuit mechanism that forced the government’s hand. Patient advocacy groups, which exist to help patients, were allegedly redirected to serve Alexion’s pricing strategy.
• The Securities Class Action complaint explicitly cited the SEC Subpoena and the FCPA investigation in its very first filing. The plaintiffs understood the connection between the two. The lower court dismissed this as unremarkable. The Delaware Supreme Court disagreed and reversed.

“The Securities Class Action alleged the same wrongdoing investigated by the SEC and disclosed by Alexion in the 2015 Notice… It is the common underlying wrongful acts that control.”

— Delaware Supreme Court opinion, Section II.C

• The Delaware Supreme Court found that the SEC investigation and the shareholder lawsuit were not two separate events. They were the same misconduct viewed from two different legal angles. The underlying conduct, Alexion’s global sales and grantmaking practices, was identical.
• The court’s ruling meant that Alexion’s own 2015 disclosure locked coverage into Tower 1. The shareholder lawsuit was deemed a claim first made in 2015, not 2016. Alexion loses the extra $20 million in Tower 2 coverage it had been pursuing for years.

Societal Impact Mapping: Who Pays When Pharma Plays Games

Public Health

The Alexion case documents a system where a pharmaceutical company’s pricing strategy was allegedly sustained by corruption, not by the legitimate value of its product.

• Soliris was priced between $500,000 and $700,000 per patient per year. With 11,000 patients worldwide, this generated billions in annual revenue. That price was not derived from a competitive market. It was derived from the monopoly status of an orphan drug in a market where patients have no alternative.
• Patients in Brazil allegedly became tools of Alexion’s pricing defense. Instead of Alexion negotiating a lower price with the Brazilian government, patient advocacy groups allegedly funded by Alexion sued the government to force reimbursement at the full price. Patients who believed these groups were fighting for them may have been funding Alexion’s profit margin instead.
• If the alleged FCPA violations in Japan, Russia, Turkey, and Brazil involved payments to public health officials, those payments corrupted the government processes that set drug coverage policy. Every patient in those countries whose coverage decision was influenced by a corrupted official was harmed by a public health system that had been compromised from the inside.
• The SEC’s investigation included documents related to the recall of certain lots of Soliris. Product safety information about a $700,000 drug for critically ill patients is not a minor disclosure matter. Inaccurate safety filings, if proven, would mean that the people most dependent on this drug were also least informed about its risks.

Economic Inequality

The economic structure of the Soliris case is a precise illustration of how pharmaceutical monopoly pricing concentrates harm at the bottom and wealth at the top.

• At $500,000 to $700,000 annually, Soliris is affordable only to patients in wealthy countries with strong insurance systems or government coverage programs. The alleged corruption of those government programs in Brazil, Russia, Turkey, and Japan means that the patients who most needed government support to access the drug were the same patients whose governments were allegedly being compromised.
• The insurers in this case collectively provided up to $190 million in D&O coverage to Alexion’s directors and officers. That is $190 million in professional protection for the executives who oversaw the alleged misconduct. The patients harmed by the sales tactics described in the class action have no equivalent financial backstop.
• The $125 million shareholder settlement went to investors, not patients. Shareholders suffered financial losses because Alexion’s stock price was allegedly inflated by misrepresentations. Patients, who suffered the direct consequences of the aggressive and allegedly unethical sales practices, received nothing from this settlement.
• The $21.5 million SEC settlement, measured against the company’s annual revenue from a single drug, represents a negligible financial penalty. The structure of this outcome, where a company can allegedly bribe foreign officials, inflate its stock through false disclosures, and settle for a small fraction of one drug’s annual revenue, is the economic architecture of impunity.
• The litigation cost of this insurance dispute, which ran from the Delaware Superior Court to the Delaware Supreme Court, was borne by the Tower 2 insurers who fought to avoid $105 million in liability. The legal machine protecting corporate wealth from accountability generates its own economy of fees, motions, and appeals that ordinary people cannot access for their own disputes.

The “Cost of a Life” Metric

What Now: Watchlist and Actions

The Delaware Supreme Court’s February 2025 ruling settled who pays the insurance bill. It did nothing to address the pricing system, the alleged bribery, or the sales tactics that generated this entire legal crisis in the first place.

Corporate Roles to Track

• Alexion Pharmaceuticals leadership and board: Alexion is now owned by AstraZeneca, which acquired it in 2021. AstraZeneca’s executives now preside over the Soliris portfolio. The decisions made about pricing, lobbying, and market access for Soliris going forward belong to them. [Note: Individual executive names are not identified in the source document]
• Tower 2 Insurer Defendants: Endurance Assurance Corporation, Swiss Re Corporate Solutions America Insurance Corporation (formerly North American Specialty Insurance Company), and Navigators Insurance Company. These are the three insurers who won this appeal. They successfully argued that Alexion’s own disclosure locked coverage into Tower 1.

Regulatory Watchlist

• U.S. Securities and Exchange Commission (SEC): Already settled with Alexion for $21.5 million in July 2020 over FCPA violations, inaccurate filings, and internal control failures. The SEC’s enforcement actions on pharmaceutical pricing, FCPA violations, and accurate investor disclosures remain active policy areas. Monitor for any follow-up enforcement related to AstraZeneca’s management of the Alexion portfolio.
• U.S. Department of Justice (DOJ): The Foreign Corrupt Practices Act violations flagged in the SEC investigation can also carry DOJ criminal jurisdiction. The $21.5 million SEC-only settlement did not foreclose parallel DOJ investigation. No DOJ action against Alexion is documented in this source material, but the FCPA exposure in four countries warrants ongoing monitoring.
• Federal Trade Commission (FTC): The FTC has expanded scrutiny of pharmaceutical pricing practices, particularly for orphan drug monopolies. Soliris represents an extreme example of a monopoly pricing structure for a rare disease drug.
• Congressional oversight bodies: The U.S. Senate has held multiple investigations into pharmaceutical pricing. Soliris has previously been cited in congressional hearings as an example of extreme orphan drug pricing. Re-engagement with the case in light of the 2025 Supreme Court ruling is warranted.

Resistance and Mutual Aid

• Support rare disease patient advocacy organizations that are financially independent of pharmaceutical companies. The Alexion case illustrates precisely how patient groups that accept pharmaceutical funding can have their mission compromised. Find groups whose funding is transparent and free of industry grants.
• Push for public disclosure of pharmaceutical FCPA settlements in your country. If you are in Brazil, Japan, Russia, or Turkey, you have a specific stake in understanding whether and how Alexion’s payments influenced your government’s drug coverage decisions. Freedom of information requests and local investigative journalism partnerships are direct tools.
• Organize around the Inflation Reduction Act drug pricing negotiation provisions in the U.S. These provisions allow Medicare to negotiate prices for a limited set of drugs. Soliris-class orphan drug monopolies are exactly the target this policy was designed for. Contact your representative to demand expansion of the negotiation list.
• If you are a current or former Alexion employee with knowledge of the sales practices described in this case, the SEC whistleblower program offers both legal protection and financial compensation for reporting securities violations. The SEC Whistleblower Office can be reached directly through the SEC website.
• Share this article with anyone currently paying out of pocket, fighting insurers, or on a waiting list for Soliris or its successor drug Ultomiris. The legal battle documented here directly affects which insurer pays for what coverage period, and the same pricing and lobbying architecture that built the Soliris monopoly now applies to Ultomiris.